Brainstorm Cell Therapeutics Inc. (BCLI) Analysts See $-0.09 EPS

September 16, 2018 - By Brian Ramirez

Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Logo

Analysts expect Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) to report $-0.09 EPS on October, 16.They anticipate $0.04 EPS change or 30.77 % from last quarter’s $-0.13 EPS. After having $-0.16 EPS previously, Brainstorm Cell Therapeutics Inc.’s analysts see -43.75 % EPS growth. The stock decreased 0.76% or $0.03 during the last trading session, reaching $3.94. About 43,286 shares traded. Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) has declined 3.97% since September 17, 2017 and is downtrending. It has underperformed by 19.59% the S&P500.

Brainstorm Cell Therapeutics Inc., a biotechnology company, develops adult stem cell therapies for neurodegenerative disorders that include amyotrophic lateral sclerosis, multiple sclerosis, Parkinson's disease, and others. The company has market cap of $81.44 million. The firm holds rights to develop and commercialize its NurOwn technology through a licensing agreement with Ramot of Tel Aviv University Ltd. It currently has negative earnings. The Company’s NurOwn technology is based on a novel differentiation protocol, which induces differentiation of the bone marrow-derived mesenchymal stem cells into neuron-supporting cells and secreting cells that release various neurotrophic factors, including glial-derived neurotrophic factor, brain-derived neurotrophic factor, vascular endothelial growth factor, and hepatocyte growth factor for the growth, survival, and differentiation of developing neurons.

More notable recent Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) news were published by: Seekingalpha.com which released: “BrainStorm’s late-stage study of NurOwn in ALS to continue as planned; shares up 4% premarket” on August 23, 2018, also Nasdaq.com with their article: “BrainStorm Cell Therapeutics Announces New Presentation Time at the HC Wainwright & Co. 20th Annual Investor …” published on September 05, 2018, Nasdaq.com published: “BrainStorm to Present at FDA and Scientific Workshops Highlighting Innovation in ALS Trial Designs and Continued …” on September 12, 2018. More interesting news about Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) were released by: Globenewswire.com and their article: “BrainStorm Appoints Arturo Araya as Chief Commercial Officer” published on September 04, 2018 as well as Globenewswire.com‘s news article titled: “BrainStorm Cell Therapeutics to Provide Corporate Update at the HC Wainwright & Co 20th Annual Investor Conference” with publication date: August 29, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.